News
A universal weakness of solid tumors opens the door to cancer treatment improvement
The study led by ICO and IDIBELL and UCSF describes, thanks to Big Data analysis, a control mechanism for DNA repair that would sensitize tumors to therapy.
A new study deciphers the mechanisms involved in antitumor activity after inhibition of ribosome synthesis
A research group from IDIBELL has published in the journal Blood their discoveries about the cellular mechanisms responsible for stopping tumor growth by blocking the formation of new ribosomes.
IDIBELL celebrates the International Day of Women and Girls in Science
At IDIBELL, we join in the visualization of women and girls in science on February 11. Over the next few days, we will organize seminars, campaigns on social networks and, we will celebrate the 4th sLHam of women scientists.
IDIBELL launches its International Ph.D. Training Program
Today is the official presentation of the International Ph.D. Training Program and personalities involved in the program will give us some details about it.
World Cancer Day
At IDIBELL we know that research saves lives. That is why we work every day to do our bit in the search for a new treatment, a new method for early detection or understanding cancer-related processes.
Depletion of NOX4 protein improves liver regeneration
A group from IDIBELL, CIBEREHD and UB shows that mice that do not express the NOX4 protein recover liver tissue more quickly after resection.
A new algorithm classifies different types of sarcoma
An international study has developed a new algorithm that classifies a wide range of sarcomas according to their molecular patterns.
Xenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors
Researchers from IDIBELL and ICO have participated in a multicenter study, published in Nature Genetics, which shows that the implantation of human tumors in nude mice does not lead to additional DNA changes.
Aptadel, the new IDIBELL’s spinoff
Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer.